RESUMEN
BACKGROUND: The mainstay treatment of nasopharyngeal cancer (NPC) is radiation therapy (RT). The doses and volumes may differ from center to center. Most studies and guidelines recommend a total dose of 60â¯Gy for elective nodal and peritumoral volume treatment. This retrospective analysis aimed to analyze whether a dose reduction to 54â¯Gy to this volume would be associated with a higher risk of recurrence. METHODS: A total of 111 patients treated by intensity-modulated radiotherapy (IMRT) and concurrent chemotherapy were retrospectively analyzed. The recurrent tumor volume was classified as "in field" if 95% of the recurrent volume was inside the 95% isodose, as "marginal" if 20-95% of the recurrence was inside the 95% isodose, or as "outside" if less than 20% of the recurrence was inside the 95% isodose. RESULTS: Median follow-up was 67 months (range 6-142). The 2 and 5year overall survival (OS) rates were 88.6% and 70%, respectively. The 2year locoregional control (LRC), disease-free survival (DFS), and distant metastasis-free survival (DMFS) were 93.3%, 89.3%, and 87.4%, and the 5year LRC, DFS, and DMFS were 86.8%, 74%, and 81.1%, respectively. Ten patients (9%) had a local and or regional recurrence. Half of the patients with locoregional failure had in-field recurrences. For primary tumor, there was no recurrence in the volume of 54 Gy. For regional lymph node volume, recurrence was detected in two (1.8%) patients in the volume of 54 Gy. CONCLUSION: These retrospective data suggest that a dose reduction may be possible for intermediate-risk volumes, especially for the primary site.
Asunto(s)
Quimioradioterapia , Neoplasias Nasofaríngeas , Recurrencia Local de Neoplasia , Dosificación Radioterapéutica , Radioterapia de Intensidad Modulada , Humanos , Masculino , Neoplasias Nasofaríngeas/radioterapia , Neoplasias Nasofaríngeas/patología , Neoplasias Nasofaríngeas/mortalidad , Neoplasias Nasofaríngeas/terapia , Femenino , Persona de Mediana Edad , Adulto , Anciano , Estudios Retrospectivos , Adulto Joven , Tasa de Supervivencia , Carga Tumoral , Supervivencia sin Enfermedad , Adolescente , Estadificación de Neoplasias , Estudios de SeguimientoRESUMEN
Radiation oncology is a field of medicine that has been rapidly growing with advances in technology, radiobiology, treatment algorithms and quality of life of modern radiotherapy over the last century. In the context of these advances, it is critical to be aware of the role of the young radiation oncologists and enable them to discover new perspectives. For this purpose, "The Young Radiation Oncologists Group" (GROG) has been established by the Turkish Society for Radiation Oncology (TROD), a subgroup which has focused on the professional developments, early career and integrating into the TROD family while supporting education and innovative research of young radiation oncologists. The purpose of this paper was to outline the structure and responsibilities of GROG and its scientific and social activities within TROD and in its own right.